EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of Spliceosome Protein SmD2 as a Potential Target for Cancer Therapy

Jing Li, Peiyu Li, Tereza Brachtlova, Ida H van der Meulen-Muileman, Henk Dekker, Vishal S Kumar, Marieke Fransen iD, Idris Bahce, Emanuela Felley-Bosco iD, Victor W van Beusechem

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252313131 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Jing Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC location Vrije Universiteit Amsterdam, Medical Oncology, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Spliceosomes, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Walter Bruckerhoff Stiftung, China Scholarship Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The core spliceosome Sm proteins are gaining attention as potential targets for cancer treatment. Here, we evaluate this, with focus on SmD2. A pan-cancer analysis including 26 solid tumor types revealed that the SmD2-encoding SNRPD2 gene was overexpressed in almost all cancers. In several cancers, high SNRPD2 expression was associated with a poor prognosis. To investigate the vulnerability of human cells to the loss of SmD2 expression, we silenced SNRPD2 using a short hairpin-expressing lentiviral vector in established cancer cell lines; in short-term cultured melanoma cells; and in several normal cell cultures, including cancer-associated fibroblasts cultured from non-small cell lung cancer resections. Additionally, we analyzed publicly available cell viability datasets for the dependency of cancer cell lines to SmD2 expression. Together, these studies clearly established SmD2 as a cancer-selective lethal target. Delving into genes with similar essentiality profiles to SNRPD2, we uncovered the intersected lethal stress between the loss of SmD2 and the loss of gene products participating in not only different mRNA processing steps including mRNA splicing, but also processes for coordinated protein production, as well as mitosis. Furthermore, we could correlate SNRPD2 expression to the responses of cancer cells to several FDA-approved anti-tumor drugs, especially to drugs inhibiting the cell cycle. Overall, our study confirms the anticipated role for targeting SmD2 in cancer treatment and reveals non-canonical SmD2 functions beyond mRNA splicing that could contribute to the dependency of cancer cells to high SNRPD2 expression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SpliceosomesNeoplasmsHumansCell Line, TumorGene Expression Regulation, NeoplasticRNA SplicingAntineoplastic AgentsMolecular Targeted Therapy

Stichwörter der Autor:innen

SNRPD2 dependencySm proteinsdrug sensitivitymitosispan-cancer analysis

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Amsterdam UMC location Vrije Universiteit Amsterdam, Medical Oncology, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
  • Cancer Center Amsterdam, Cancer Biology and Immunology, 1081 HV Amsterdam, The Netherlands.
  • ORCA Therapeutics BV, Onderwijsboulevard 225, 5223 DE 's-Hertogenbosch, The Netherlands.
  • Amsterdam Institute for Infection and Immunity, Cancer Immunology, 1081 HV Amsterdam, The Netherlands.
  • Amsterdam UMC location Vrije Universiteit Amsterdam, Pulmonary Medicine, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
  • Cancer Center Amsterdam, Cancer Treatment and Quality of Life, 1081 HV Amsterdam, The Netherlands.

ORCID-Profile: Marieke Fransen, Emanuela Felley-Bosco

Förderung

  • Walter Bruckerhoff Stiftung
  • China Scholarship Council

Zitieren

APA

Li, J., Li, P., Brachtlova, T., van der Meulen-Muileman, I. H., Dekker, H., Kumar, V. S., Fransen, M., Bahce, I., Felley-Bosco, E., & van Beusechem, V. W. (2024). Evaluation of Spliceosome Protein SmD2 as a Potential Target for Cancer Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252313131

Vancouver

Li J, Li P, Brachtlova T, van der Meulen-Muileman IH, Dekker H, Kumar VS, et al. Evaluation of Spliceosome Protein SmD2 as a Potential Target for Cancer Therapy. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252313131

BibTeX
@article{Li2024,
  author = {Li, Jing and Li, Peiyu and Brachtlova, Tereza and van der Meulen-Muileman, Ida H and Dekker, Henk and Kumar, Vishal S and Fransen, Marieke and Bahce, Idris and Felley-Bosco, Emanuela and van Beusechem, Victor W},
  title = {Evaluation of Spliceosome Protein SmD2 as a Potential Target for Cancer Therapy},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252313131}
}
Kostenlos starten →